Application of Nanomaterials in Biomedical Imaging and Cancer Therapy

Siddique, Sarkar; Chow, James C. L.

doi:10.3390/nano10091700

Cited by 236 publications

(159 citation statements)

References 225 publications

(206 reference statements)

Supporting

Mentioning

158

Contrasting

Unclassified

Order By: Relevance

“…Various materials including microspheres, mesoporous, micro/nanoparticles, liposomes, micelles, and emulsions were developed as effective drug carriers [ 4 ]. Currently, a wide range of nanoparticles are being advanced to serve as potential carriers for delivering drugs in a controlled mode to specific-targeted sites in the human body [ 5 , 6 , 7 , 8 ]. These nano-sized systems have a remarkable aptitude for the targeted delivery of a specific drug dose to specific cells (such as cancer cells), without disturbing the physiology of the normal cells [ 9 ].…”

Section: Introductionmentioning

confidence: 99%

Formulation of Quaternized Aminated Chitosan Nanoparticles for Efficient Encapsulation and Slow Release of Curcumin

et al. 2021

View full text Add to dashboard Cite

An effective drug nanocarrier was developed on the basis of a quaternized aminated chitosan (Q-AmCs) derivative for the efficient encapsulation and slow release of the curcumin (Cur)-drug. A simple ionic gelation method was conducted to formulate Q-AmCs nanoparticles (NPs), using different ratios of sodium tripolyphosphate (TPP) as an ionic crosslinker. Various characterization tools were employed to investigate the structure, surface morphology, and thermal properties of the formulated nanoparticles. The formulated Q-AmCs NPs displayed a smaller particle size of 162 ± 9.10 nm, and higher surface positive charges, with a maximum potential of +48.3 mV, compared to native aminated chitosan (AmCs) NPs (231 ± 7.14 nm, +32.8 mV). The Cur-drug encapsulation efficiency was greatly improved and reached a maximum value of 94.4 ± 0.91%, compared to 75.0 ± 1.13% for AmCs NPs. Moreover, the in vitro Cur-release profile was investigated under the conditions of simulated gastric fluid [SGF; pH 1.2] and simulated colon fluid [SCF; pH 7.4]. For Q-AmCs NPs, the Cur-release rate was meaningfully decreased, and recorded a cumulative release value of 54.0% at pH 7.4, compared to 73.0% for AmCs NPs. The formulated nanoparticles exhibited acceptable biocompatibility and biodegradability. These findings emphasize that Q-AmCs NPs have an outstanding potential for the delivery and slow release of anticancer drugs.

show abstract

Section: Introductionmentioning

confidence: 99%

Formulation of Quaternized Aminated Chitosan Nanoparticles for Efficient Encapsulation and Slow Release of Curcumin

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Additionally, the kinetics of release was studied using a 5-fold dilution of the suspension (at a doxorubicin concentration of approximately 340 µg/mL). At pre-determined time points (1,2,3,4,6,24,48, and 120 h), samples with a volume of 1.5 mL were collected and the nanoparticles were separated from the release medium by centrifugation (48,254× g, 30 min) at a temperature of +5 • C in an Avanti JXN-30 centrifuge (Beckman Coulter, Pasadena, CA, USA). For comparison, centrifugation at a lower speed was evaluated (15,000× g).…”

Section: In Vitro Release Studies Using Simplified Release Mediamentioning

confidence: 99%

Exploring the Interplay between Drug Release and Targeting of Lipid-Like Polymer Nanoparticles Loaded with Doxorubicin

et al. 2021

View full text Add to dashboard Cite

Targeted delivery of doxorubicin still poses a challenge with regards to the quantities reaching the target site as well as the specificity of the uptake. In the present approach, two colloidal nanocarrier systems, NanoCore-6.4 and NanoCore-7.4, loaded with doxorubicin and characterized by different drug release behaviors were evaluated in vitro and in vivo. The nanoparticles utilize a specific surface design to modulate the lipid corona by attracting blood-borne apolipoproteins involved in the endogenous transport of chylomicrons across the blood–brain barrier. When applying this strategy, the fine balance between drug release and carrier accumulation is responsible for targeted delivery. Drug release experiments in an aqueous medium resulted in a difference in drug release of approximately 20%, while a 10% difference was found in human serum. This difference affected the partitioning of doxorubicin in human blood and was reflected by the outcome of the pharmacokinetic study in rats. For the fast-releasing formulation NanoCore-6.4, the AUC0→1h was significantly lower (2999.1 ng × h/mL) than the one of NanoCore-7.4 (3589.5 ng × h/mL). A compartmental analysis using the physiologically-based nanocarrier biopharmaceutics model indicated a significant difference in the release behavior and targeting capability. A fraction of approximately 7.310–7.615% of NanoCore-7.4 was available for drug targeting, while for NanoCore-6.4 only 5.740–6.057% of the injected doxorubicin was accumulated. Although the targeting capabilities indicate bioequivalent behavior, they provide evidence for the quality-by-design approach followed in formulation development.

show abstract

“…Synthetic nanoparticles such as liposomes, dendrimers, and carbon nanotubes have been designed for the targeting of tumors at multiple sites [ 150 ]. These particles are substantially larger ( Figure 2 and Table 1 ) than molecular targeting agents such as peptides (≈1 nm) and IgG antibodies (10 nm) [ 151 ], and they are not as flexible as living cells, but they are still able to enter endothelial pores (fenestrae ≈10 nm–2 μm) and penetrate (tumor) tissues efficiently [ 152 ].…”

Section: Synthetic Nanoparticles For Igsmentioning

confidence: 99%

Cell-Based Tracers as Trojan Horses for Image-Guided Surgery

Sier

Vries

Vorst

et al. 2021

IJMS

View full text Add to dashboard Cite

Surgeons rely almost completely on their own vision and palpation to recognize affected tissues during surgery. Consequently, they are often unable to distinguish between different cells and tissue types. This makes accurate and complete resection cumbersome. Targeted image-guided surgery (IGS) provides a solution by enabling real-time tissue recognition. Most current targeting agents (tracers) consist of antibodies or peptides equipped with a radiolabel for Positron Emission Tomography (PET) and Single Photon Emission Computed Tomography (SPECT), magnetic resonance imaging (MRI) labels, or a near-infrared fluorescent (NIRF) dye. These tracers are preoperatively administered to patients, home in on targeted cells or tissues, and are visualized in the operating room via dedicated imaging systems. Instead of using these ‘passive’ tracers, there are other, more ‘active’ approaches of probe delivery conceivable by using living cells (macrophages/monocytes, neutrophils, T cells, mesenchymal stromal cells), cell(-derived) fragments (platelets, extracellular vesicles (exosomes)), and microorganisms (bacteria, viruses) or, alternatively, ‘humanized’ nanoparticles. Compared with current tracers, these active contrast agents might be more efficient for the specific targeting of tumors or other pathological tissues (e.g., atherosclerotic plaques). This review provides an overview of the arsenal of possibilities applicable for the concept of cell-based tracers for IGS.

show abstract

Application of Nanomaterials in Biomedical Imaging and Cancer Therapy

Cited by 236 publications

References 225 publications

Formulation of Quaternized Aminated Chitosan Nanoparticles for Efficient Encapsulation and Slow Release of Curcumin

Formulation of Quaternized Aminated Chitosan Nanoparticles for Efficient Encapsulation and Slow Release of Curcumin

Exploring the Interplay between Drug Release and Targeting of Lipid-Like Polymer Nanoparticles Loaded with Doxorubicin

Cell-Based Tracers as Trojan Horses for Image-Guided Surgery

Contact Info

Product

Resources

About